In the treatment of MM, it seems to be an appropriate approach based on combination therapy on the condition that monotherapy with PD-1/PD-L1 MAbs had yielded unsatisfactory outcomes [33, 34]; the MAbs targeting PD-1/PD-L1 include pembrolizumab, durvalumab, and nivolumab. This evidence concerns the gene CD274 and Miyoshi myopathy.